1

Ascendis Pharma

#2076

Rank

$7.79B

Marketcap

DK Denmark

Country

Ascendis Pharma
Leadership team

Mr. Jan Moller Mikkelsen (Pres, CEO, Member of Exec. Board & Exec. Director)

Mr. Michael Wolff Jensen L.L.M. (Sr. VP, Chief Legal Officer & Member of the Exec. Board)

Dr. Birgitte Volck M.D., Ph.D. (Sr. VP and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs)

Products/ Services
Biotechnology, Clinical Trials, Health Care
Number of Employees
500 - 1000
Headquarters
Palo Alto, California, United States
Established
2006
Company Registration
SEC CIK number: 0001612042
Revenue
20M - 100M
Traded as
ASND
Social Media
Overview
Location
Summary
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
History

Ascendis Pharma was founded in 2005 in Copenhagen, Denmark with the mission of revolutionizing treatments for rare and complex diseases. The company built a robust platform with state-of-the-art drug development technologies to provide new treatments for diseases with few or no available treatments.

Mission
Ascendis Pharma creates technologies to transform medicine and enable treatments to reach those with rare and complex diseases across the globe.
Vision
Ascendis Pharma will be recognized as the leader in the development of transformative treatments for rare and complex diseases that provide superior therapeutic benefit with improved convenience and compliance.
Key Team

Mr. Scott T. Smith (CFO, Sr. VP & Member of Exec. Board)

Ms. Lotte Sonderbjerg (Chief Admin. Officer, Sr. VP & Member of the Exec. Board)

Mr. Flemming Steen Jensen (Sr. VP of Product Supply & Quality)

Mr. Peter Rasmussen (VP of Fin. & Principal Accounting Officer)

Dr. Kennett Sprogoe (Sr. VP and Head of Innovation & Research)

Mr. Timothy J. Lee (Sr. Director of Investor Relations)

Dr. Jens Sigurd Okkels Ph.D. (Sr. VP of Product Devel.)

Recognition and Awards
In 2019, Ascendis Pharma received Orphan Drug Designation and Priority Review Status from the FDA for TransCon hGH, an investigational once-weekly, long-acting recombinant human growth hormone therapy. In 2020, they were also awarded the prestigious Frost & Sullivan Digital Health Ecosystem Enabler Award.
References
Ascendis Pharma
Leadership team

Mr. Jan Moller Mikkelsen (Pres, CEO, Member of Exec. Board & Exec. Director)

Mr. Michael Wolff Jensen L.L.M. (Sr. VP, Chief Legal Officer & Member of the Exec. Board)

Dr. Birgitte Volck M.D., Ph.D. (Sr. VP and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs)

Products/ Services
Biotechnology, Clinical Trials, Health Care
Number of Employees
500 - 1000
Headquarters
Palo Alto, California, United States
Established
2006
Company Registration
SEC CIK number: 0001612042
Revenue
20M - 100M
Traded as
ASND
Social Media